Clinical trials: Pulmonary Artery Hypertension
Pulmonary Vascular Disease, Pulmonary Arterial Hypertension
High Altitude (HA) Residents With Pulmonary Vascular Diseseases (PVD), Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) vs Sea Level (LA)
To study the effect of relocation from 2840m (Quito) to sea level (Pedernales) in patients with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension (PH)…
- Conditions
- Pulmonary Vascular Disease, Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
- Trial name
- NCT06092424
- Testing
- Relocation from HA to LA
- Where
- Switzerland
- Volunteers
- 36 people
- Sponsor
- University of Zurich
Pulmonary Arterial Hypertension
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
The AC-055-302/SERAPHIN study will be an event-driven Phase III study, comparing two different doses of macitentan (ACT-064992) (3 and 10 mg) vs placebo in patients with symptomatic PAH.
- Trial name
- SERAPHIN (NCT00660179)
- Testing
- macitentan (ACT-064992)
- Where
- 153 sites in United States, Argentina and 36 more
- Volunteers
- 742 people
- Sponsor
- Actelion
Pulmonary Artery Hypertension
Potts-shunt for the Treatment of Pediatric Patients With Severe Pulmonary Hypertension
This is a multi-center, perspective, and exploratory study aimed at evaluating the 3-years clinical outcome of Potts-shunt procedure for pediatric patients with severe pulmonary artery hypertension (PAH).
- Trial name
- NCT06429579
- Testing
- Comprehensive therapy combined Potts-shunt procedure and conventional drug therapy, Only conventional drug therapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- China National Center for Cardiovascular Diseases
Pulmonary Arterial Hypertension
Myocardial Work Evaluation in Patients With PAH
Right ventricular function is a key determinant of survival in patients with pulmonary arterial hypertension, with right heart failure being the leading cause of death.
- Trial name
- NCT06567379
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Central Hospital, Nancy, France
Pulmonary Arterial Hypertension
Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)
The purpose of this study is to assess the safety and tolerability of sorafenib in patients with PAH already on existing therapy with a prostacyclin [epoprostenol (Flolan)], treprostinil (Remodulin), or iloprost alone, or with or…
- Trial name
- NCT00452218
- Testing
- Sorafenib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Chicago
Pulmonary Arterial Hypertension
A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses
Sitaxsentan has a low drug-drug interaction potential and it did not have a clinically relevant effect on pharmacokinetics of sildenafil (a CYP3A sensitive substrate and PDE5 inhibitor).
- Trial name
- NCT01244620
- Testing
- sitaxentan, tadalafil, sitaxsentan
- Where
- Singapore
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pulmonary Arterial Hypertension, Hypertension, Pulmonary
Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening disease. In many patients, the course of PAH is a steady deterioration and reduced life expectancy.
- Trial name
- NCT01642407
- Testing
- Sildenafil
- Where
- 5 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypertension,Pulmonary
The Screening and Analysis of Plasma Biomarkers in Irreversible PAH-CHD
The purpose of this study is to analyse the sensitivity and specificity of circulating endothelial cells to predict irreversible pulmonary arterial hypertension associated with congenital heart disease.
- Trial name
- NCT02267200
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Idiopathic Pulmonary Arterial Hypertension
Safety and Feasibility of Autologous Endothelial Progenitor Cells Transplantation in Patients With Idiopathic Pulmonary Arterial Hypertension
Recent researches indicate that impairment of vascular and endothelial homeostasis plays a major role in the initiation and development of IPAH.We have recently reported the safety and feasibility data for autologous endothelial…
- Trial name
- NCT00641836
- Testing
- Transplantation of autologous endothelial progenitor cells
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Zhejiang University
Pulmonary Arterial Hypertension (PAH)
Long-Term Outcomes of Selexipag in Schistosomiasis-Associated Pulmonary Arterial Hypertension
Schistosomiasis-associated pulmonary arterial hypertension is a serious condition that can lead to shortness of breath, heart failure, frequent hospitalizations, and early death.
- Trial name
- PROPULSE-Sch (NCT07453030)
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Caio Júlio César dos Santos Fernandes
Pulmonary Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Right Atrial Fibrosis in Pulmonary Hypertension
The study aim to assess right atrial (RA) remodeling, in terms of RA fibrosis, in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension patients.
- Conditions
- Pulmonary Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Arterial Hypertension
- Trial name
- RAFE-PH (NCT04663230)
- Testing
- cardiac magnetic resonance imaging
- Where
- 2 sites in Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Giessen
Adherence, Medication
Prevalence and Determinants of Therapeutic Non-Compliance in Patients With Chronic Pathologies ( PDTNCCP)
Identify the prevalence and determinants related to therapeutic non adherence among patients with chronic pathologies and to design effective interventions optimizing treatment compliance.
- Trial name
- PDTNCCP (NCT07864532)
- Where
- Tunisia
- Volunteers
- 3,000 people
- Sponsor
- University of Monastir
Pulmonary Arterial Hypertension (PAH)
A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag
This study will look at safety and tolerability of LIQ861 (treprostinil) inhalation powder in adults with pulmonary arterial hypertension (PAH, WHO Group 1) who switch from selexipag, a medicine taken by mouth, to treprostinil, a…
- Trial name
- NCT07759804
- Testing
- LIQ861 (treprostinil) inhalation powder
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Liquidia Technologies, Inc.
Pulmonary Arterial Hypertension (PAH)
Bioequivalence Study to Compare Selexipag 400mcg Film Coated Tablets (400 mcg Selexipag) Versus Uptravi® 400mcg Film Coated Tablets (400 mcg Selexipag)
Randomized, single oral dose, two-period, two-treatment, two-sequence open-label, crossover, bioequivalence study to compare Selexipag 400mcg Film Coated Tablets (400 mcg Selexipag) versus Uptravi® 400mcg Film Coated Tablets (400…
- Trial name
- NCT06932198
- Testing
- Selexipag Film Coated Tablets, Uptravi® Film Coated Tablets
- Where
- Jordan
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Acute Response of Iloprost Inhalation Using the Breelib Nebulizer in Pulmonary Arterial Hypertension
Primary objective To evaluate the effect of rapid inhalation of 2.5μgiloprost using the Breelib nebulizer on pulmonary vascular resistance (PVR) in patients with pulmonary arterial hypertension Secondary objectives To evaluate…
- Trial name
- NCT03365479
- Testing
- Iloprost
- Where
- 2 sites in Germany
- Volunteers
- 30 people
- Sponsor
- University of Giessen
Eisenmenger Syndrome
Bosentan in Treatment of Pulmonary Arterial Hypertension
Eisenmenger's syndrome presents as a severe clinical picture of polymorbidity that constitutes a great burden at the individual as well as the familial and social level.
- Trial name
- NCT00266162
- Testing
- Bosentan administration
- Where
- 8 sites in Germany
- Volunteers
- 60 people
- Sponsor
- Competence Network for Congenital Heart Defects
Pulmonary Hypertension
The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting
A Comparison of Safety and Inhalation Times of Ventavis (iloprost) Inhalation Solution delivered by I-Neb Utilizing Power Disc-6 and Power Disc-15 "Power 15 Study"
- Trial name
- NCT00467896
- Testing
- Iloprost PD-6, Iloprost PD-15
- Where
- 12 sites in United States
- Volunteers
- 62 people
- Sponsor
- Actelion
Sleep Disorders
Screening for Sleep Hypoxemia in Pulmonary Arterial Hypertension
In the investigators study, and regarding results of small cohorts in the literature, the investigators hypothesize that hypoxemia is frequent in IPAH and CPEPH.
- Trial name
- Sommeil_HTAP (NCT01371669)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjects
Study ROR-PH-302, ADVANCE CAPACITY, was designed to evaluate the effects of ralinepag therapy on exercise capacity as assessed by change in peak oxygen consumption (VO2) derived from cardiopulmonary exercise testing (CPET) after…
- Trial name
- CAPACITY (NCT04084678)
- Testing
- Ralinepag
- Where
- 33 sites in United States, Argentina and 10 more
- Volunteers
- 10 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.
A phase 3, randomized, double-blind, placebo-controlled study to assess safety and efficacy of ambrisentan in subjects with pulmonary arterial hypertension.
- Trial name
- NCT00423748
- Testing
- ambrisentan
- Volunteers
- 186 people
- Sponsor
- Gilead Sciences